CRDF Earnings — Cardiff Oncology, Inc. Common Stock Post-ER Performance | BigEarnings
CRDF — Cardiff Oncology, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$0.94
Market Cap$73.1M
P/E—
52W Range$0.76 – $3.31
Next Earnings2026-11-05
About Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
